Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Final outcomes of a phase 2 trial. Read more about Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Final outcomes of a phase 2 trial.
Optimizing pancreatic cancer management with next generation imaging and liquid biopsy (CHANGE-PDAC). Read more about Optimizing pancreatic cancer management with next generation imaging and liquid biopsy (CHANGE-PDAC).
Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC) Read more about Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)
Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC) Read more about Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)
Characterizing attitudes related to child-bearing in young women diagnosed with early breast cancer (EBC). Read more about Characterizing attitudes related to child-bearing in young women diagnosed with early breast cancer (EBC).
Improving oral oncolytic education in a safety-net outpatient hematology-oncology practice. Read more about Improving oral oncolytic education in a safety-net outpatient hematology-oncology practice.
Predictors of high financial distress in a national, multiethnic sample of patients with cancer. Read more about Predictors of high financial distress in a national, multiethnic sample of patients with cancer.
Evaluating changes in “good safety monitoring” for cancer clinical trial participants during the COVID-19 pandemic. Read more about Evaluating changes in “good safety monitoring” for cancer clinical trial participants during the COVID-19 pandemic.
The marginal diagnostic benefit of pancreatic cancer molecular profiling after germline testing. Read more about The marginal diagnostic benefit of pancreatic cancer molecular profiling after germline testing.
Rate of skeletal-related events (SREs) for abiraterone acetate (AA) versus enzalutamide (ENZ) in prostate cancer: A population-based study using the SEER-Medicare database. Read more about Rate of skeletal-related events (SREs) for abiraterone acetate (AA) versus enzalutamide (ENZ) in prostate cancer: A population-based study using the SEER-Medicare database.
